The present invention relates to the Janus kinase (JAK) inhibitors3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H--pyrazol-1-yl]octanenitrile or 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H- pyrazol-1-yl]heptanenitrile, as well asits compositionsand methods of use, which is useful in the treatment of JAK-associateddiseases including, for example, inflammatory andautoim-mune disorders, skin disorders, cancer, and other diseases.